Novel Acetamide-Based HO-1 Inhibitor Counteracts Glioblastoma Progression by Interfering with the Hypoxic-Angiogenic
Agata Grazia D'Amico1, Grazia Maugeri2, Luca Vanella1
1Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
International Journal of Molecular Sciences
|May 25, 2024
Summary
This study reveals that hypoxia in glioblastoma (GBM) upregulates heme oxygenase-1 (HO-1). Inhibiting HO-1 effectively counteracts GBM progression by targeting the HIFα/HO-1/VEGF pathway in aggressive cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer characterized by uncontrolled cell proliferation and hypoxic microenvironments.
- Hypoxia induces signaling pathways, including hypoxic inducible factor (HIF) and vascular endothelial growth factor (VEGF), promoting cancer progression.
- Heme oxygenase-1 (HO-1) is an antioxidant enzyme implicated in cancer aggressiveness.
Purpose of the Study:
- To investigate the relationship between HO-1 expression and the hypoxic microenvironment in GBM.
- To evaluate the efficacy of a novel HO-1 inhibitor (VP18/58) in targeting GBM progression.
Main Methods:
- Cultured human glioblastoma cell lines (U87MG and A172) under hypoxic conditions using deferoxamine (DFX).
- Assessed HO-1 expression and localization in response to hypoxia.
- Tested the effect of the HO-1 inhibitor VP18/58 on GBM progression and the HIFα/HO-1/VEGF signaling cascade.
Main Results:
- Hypoxic conditions led to increased HO-1 expression and nuclear localization in a cell-dependent manner, correlating with malignant phenotype.
- The HO-1 inhibitor VP18/58 demonstrated a counteracting effect on GBM progression.
- VP18/58 modulated the HIFα/HO-1/VEGF signaling pathway in more malignant GBM cells.
Conclusions:
- HO-1 upregulation is linked to the hypoxic microenvironment in GBM.
- Targeting HO-1 with VP18/58 represents a potential therapeutic strategy for GBM, particularly in aggressive phenotypes.
- Modulating the HIFα/HO-1/VEGF cascade is a key mechanism by which HO-1 inhibition impacts GBM progression.
Keywords:
HO-1 geneHO-1 inhibitorsangiogenesisglioblastoma multiformehypoxiavascular endothelial growth factorMore Related Videos
Related Concept Videos
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K